STOCK TITAN

[Form 4] LeMaitre Vascular, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

LeMaitre Vascular director John James O'Connor reported changes in beneficial ownership on Form 4 relating to dividend equivalent rights that accrued on previously granted equity awards. The filing shows transactions dated 09/04/2025 recording a series of small accruals of dividend equivalent rights tied to restricted stock units and performance share unit awards granted on 12/12/2022, 12/8/2023 and 12/6/2024. Each dividend equivalent right is described as the economic equivalent of one share of the issuer's common stock. The filing was signed by Nathan Ulrich on 09/08/2025. The report indicates the form was filed by one reporting person who is a director of the issuer (LMAT).

Il direttore di LeMaitre Vascular, John James O'Connor, ha segnalato variazioni nella titolarità beneficiaria nel modulo 4 riguardanti diritti equivalenti ai dividendi maturati su precedenti assegnazioni di azioni. La comunicazione indica transazioni datate 04/09/2025 che registrano una serie di piccoli accantonamenti di diritti equivalenti ai dividendi collegati a unità azionarie vincolate (RSU) e a unità azionarie legate alle prestazioni (PSU) assegnate il 12/12/2022, 12/08/2023 e 12/06/2024. Ciascun diritto equivalente al dividendo è descritto come l'equivalente economico di una azione ordinaria dell'emittente. Il documento è stato firmato da Nathan Ulrich il 08/09/2025. La segnalazione indica che il modulo è stato presentato da una sola persona interessata, che è un direttore dell'emittente (LMAT).

El director de LeMaitre Vascular, John James O'Connor, informó cambios en la propiedad beneficiaria en el Formulario 4 relacionados con derechos equivalentes a dividendos que se acumularon sobre adjudicaciones de capital otorgadas anteriormente. La presentación muestra transacciones fechadas el 04/09/2025 que registran una serie de pequeños acumulaciones de derechos equivalentes a dividendos vinculados a unidades de acciones restringidas y a unidades de acciones por desempeño otorgadas el 12/12/2022, 12/08/2023 y 12/06/2024. Cada derecho equivalente al dividendo se describe como el equivalente económico de una acción ordinaria del emisor. La presentación fue firmada por Nathan Ulrich el 08/09/2025. El informe indica que el formulario fue presentado por una sola persona informante que es director del emisor (LMAT).

LeMaitre Vascular 이사 존 제임스 오코너가 이전에 부여된 지분 보상에 대해 발생한 배당금 등가권에 관한 유익소유권 변경을 양식 4에 보고했습니다. 제출서류에는 2025-09-04자로 된 거래들이 기재되어 있으며, 12/12/2022, 12/08/2023, 12/06/2024에 부여된 제한주식단위(RSU) 및 성과주식단위(PSU) 보상과 연계된 소액의 배당금 등가권 누적이 기록되어 있습니다. 각 배당금 등가권은 발행회사의 보통주 1주에 해당하는 경제적 등가물로 설명되어 있습니다. 해당 서류는 2025-09-08에 네이선 울리히가 서명했습니다. 보고서에는 이 양식이 발행인(LMAT)의 이사인 한 명의 보고자가 제출했음이 기재되어 있습니다.

John James O'Connor, administrateur de LeMaitre Vascular, a déclaré des changements de propriété bénéficiaire sur le formulaire 4 concernant des droits équivalents aux dividendes qui se sont accumulés sur des attributions d'actions antérieures. Le dépôt indique des transactions datées du 04/09/2025 enregistrant une série de petits accumulations de droits équivalents aux dividendes liés à des unités d'actions restreintes et à des unités d'actions de performance attribuées le 12/12/2022, le 12/08/2023 et le 12/06/2024. Chaque droit équivalent au dividende est décrit comme l'équivalent économique d'une action ordinaire de l'émetteur. Le dossier a été signé par Nathan Ulrich le 08/09/2025. Le rapport indique que le formulaire a été déposé par une seule personne déclarante, qui est administrateur de l'émetteur (LMAT).

LeMaitre Vascular-Direktor John James O'Connor meldete Änderungen des wirtschaftlich Berechtigten in Formular 4 in Bezug auf Dividendengleichwertrechte, die auf zuvor gewährte Aktienzuteilungen angesammelt wurden. Die Einreichung zeigt Transaktionen vom 04.09.2025, die eine Reihe kleiner Ansammlungen von Dividendengleichwertrechten dokumentieren, die an Restricted Stock Units und Performance Share Units gebunden sind, die am 12/12/2022, 12/08/2023 und 12/06/2024 gewährt wurden. Jedes Dividendengleichwertrecht wird als wirtschaftliches Äquivalent einer Stammaktie des Emittenten beschrieben. Die Einreichung wurde am 08.09.2025 von Nathan Ulrich unterzeichnet. Der Bericht gibt an, dass das Formular von einer meldenden Person eingereicht wurde, die Direktor des Emittenten (LMAT) ist.

Positive
  • Transparent disclosure of dividend equivalent accruals tied to prior RSU and PSU awards
  • Reporting person identified as a director and the filing lists specific grant dates for the underlying awards
Negative
  • None.

Insights

TL;DR: Routine accrual of dividend equivalents on prior equity awards for a director; no cash transactions or option exercises reported.

The Form 4 documents accrual entries for dividend equivalent rights that vest proportionately with underlying restricted stock units and performance share units granted on specific prior grant dates. These entries are administrative in nature, reflecting earned economic equivalents rather than open-market purchases or sales. The reporting person is identified as a director and the filing was singular (one reporting person). The signature block shows the filing was signed by Nathan Ulrich on 09/08/2025, consistent with standard Form 4 execution practices.

TL;DR: Non-cash accruals of dividend equivalent rights recorded; no change to cash position or debt reported.

The transactions dated 09/04/2025 list multiple fractional amounts of dividend equivalent rights tied to RSU and PSU awards from 12/12/2022, 12/08/2023 and 12/06/2024. Each right is stated as economically equivalent to one share of common stock and several fractional amounts were reported as acquired (A) with $0 price, indicating accrual rather than purchase. The filing does not disclose any exercised derivatives, sales, purchases, or changes in indebtedness. Materiality appears limited to award accrual accounting for the reporting person.

Il direttore di LeMaitre Vascular, John James O'Connor, ha segnalato variazioni nella titolarità beneficiaria nel modulo 4 riguardanti diritti equivalenti ai dividendi maturati su precedenti assegnazioni di azioni. La comunicazione indica transazioni datate 04/09/2025 che registrano una serie di piccoli accantonamenti di diritti equivalenti ai dividendi collegati a unità azionarie vincolate (RSU) e a unità azionarie legate alle prestazioni (PSU) assegnate il 12/12/2022, 12/08/2023 e 12/06/2024. Ciascun diritto equivalente al dividendo è descritto come l'equivalente economico di una azione ordinaria dell'emittente. Il documento è stato firmato da Nathan Ulrich il 08/09/2025. La segnalazione indica che il modulo è stato presentato da una sola persona interessata, che è un direttore dell'emittente (LMAT).

El director de LeMaitre Vascular, John James O'Connor, informó cambios en la propiedad beneficiaria en el Formulario 4 relacionados con derechos equivalentes a dividendos que se acumularon sobre adjudicaciones de capital otorgadas anteriormente. La presentación muestra transacciones fechadas el 04/09/2025 que registran una serie de pequeños acumulaciones de derechos equivalentes a dividendos vinculados a unidades de acciones restringidas y a unidades de acciones por desempeño otorgadas el 12/12/2022, 12/08/2023 y 12/06/2024. Cada derecho equivalente al dividendo se describe como el equivalente económico de una acción ordinaria del emisor. La presentación fue firmada por Nathan Ulrich el 08/09/2025. El informe indica que el formulario fue presentado por una sola persona informante que es director del emisor (LMAT).

LeMaitre Vascular 이사 존 제임스 오코너가 이전에 부여된 지분 보상에 대해 발생한 배당금 등가권에 관한 유익소유권 변경을 양식 4에 보고했습니다. 제출서류에는 2025-09-04자로 된 거래들이 기재되어 있으며, 12/12/2022, 12/08/2023, 12/06/2024에 부여된 제한주식단위(RSU) 및 성과주식단위(PSU) 보상과 연계된 소액의 배당금 등가권 누적이 기록되어 있습니다. 각 배당금 등가권은 발행회사의 보통주 1주에 해당하는 경제적 등가물로 설명되어 있습니다. 해당 서류는 2025-09-08에 네이선 울리히가 서명했습니다. 보고서에는 이 양식이 발행인(LMAT)의 이사인 한 명의 보고자가 제출했음이 기재되어 있습니다.

John James O'Connor, administrateur de LeMaitre Vascular, a déclaré des changements de propriété bénéficiaire sur le formulaire 4 concernant des droits équivalents aux dividendes qui se sont accumulés sur des attributions d'actions antérieures. Le dépôt indique des transactions datées du 04/09/2025 enregistrant une série de petits accumulations de droits équivalents aux dividendes liés à des unités d'actions restreintes et à des unités d'actions de performance attribuées le 12/12/2022, le 12/08/2023 et le 12/06/2024. Chaque droit équivalent au dividende est décrit comme l'équivalent économique d'une action ordinaire de l'émetteur. Le dossier a été signé par Nathan Ulrich le 08/09/2025. Le rapport indique que le formulaire a été déposé par une seule personne déclarante, qui est administrateur de l'émetteur (LMAT).

LeMaitre Vascular-Direktor John James O'Connor meldete Änderungen des wirtschaftlich Berechtigten in Formular 4 in Bezug auf Dividendengleichwertrechte, die auf zuvor gewährte Aktienzuteilungen angesammelt wurden. Die Einreichung zeigt Transaktionen vom 04.09.2025, die eine Reihe kleiner Ansammlungen von Dividendengleichwertrechten dokumentieren, die an Restricted Stock Units und Performance Share Units gebunden sind, die am 12/12/2022, 12/08/2023 und 12/06/2024 gewährt wurden. Jedes Dividendengleichwertrecht wird als wirtschaftliches Äquivalent einer Stammaktie des Emittenten beschrieben. Die Einreichung wurde am 08.09.2025 von Nathan Ulrich unterzeichnet. Der Bericht gibt an, dass das Formular von einer meldenden Person eingereicht wurde, die Direktor des Emittenten (LMAT) ist.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
O'Connor John James

(Last) (First) (Middle)
C/O LEMAITRE VASCULAR, INC.
63 SECOND AVENUE

(Street)
BURLINGTON MA 01803

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/04/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Dividend Equivalent Rights (1) 09/04/2025 A 0.4173 (1) (1) Common Stock 0.4173 $0 6.5156 D
Dividend Equivalent Rights (2) 09/04/2025 A 0.4173 (2) (2) Common Stock 0.4173 $0 5.5269 D
Dividend Equivalent Rights (3) 09/04/2025 A 0.7138 (3) (3) Common Stock 0.7138 $0 5.3975 D
Dividend Equivalent Rights (4) 09/04/2025 A 0.8546 (4) (4) Common Stock 0.8546 $0 5.8691 D
Dividend Equivalent Rights (5) 09/04/2025 A 0.8697 (5) (5) Common Stock 0.8697 $0 2.9094 D
Explanation of Responses:
1. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
2. These dividend equivalent rights accrued on a Performance Share Unit (PSU) award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
3. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
4. These dividend equivalent rights accrued on a Performance Share Unit (PSU) award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
5. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
/s/ Nathan Ulrich 09/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did John James O'Connor report on the Form 4 for LMAT?

He reported accruals of dividend equivalent rights on 09/04/2025 related to prior RSU and PSU awards; each is the economic equivalent of one share.

Do the transactions on this Form 4 involve purchases or sales of stock?

No. The entries are recorded as accruals of dividend equivalent rights with a $0 price, not open-market purchases or sales.

Which grant dates produced the dividend equivalent rights reported?

The dividend equivalents accrued on awards granted on 12/12/2022, 12/08/2023, and 12/06/2024.

When were the transactions and when was the Form 4 signed?

Transactions are dated 09/04/2025 and the Form 4 bears a signature by Nathan Ulrich dated 09/08/2025.

Was the Form 4 filed by more than one reporting person?

No. The form indicates it was filed by one reporting person.
Lemaitre Vasculr

NASDAQ:LMAT

LMAT Rankings

LMAT Latest News

LMAT Latest SEC Filings

LMAT Stock Data

2.09B
20.87M
7.8%
95.11%
5.96%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
BURLINGTON